On September 20, 2019, the FDA officially approved the marketing application of semaglutide for improving blood sugar control in patients with type 2 diabetes in combination with diet and exercise. Semaglutide is a human GLP-1 analogue with high albumin affinity and a long half-life, enabling once-weekly administration to stimulate insulin secretion and inhibit glucagon secretion in a blood sugar-dependent manner.
Semaglutide is a GLP-1 receptor agonist synthesized via solid-phase peptide synthesis. Its molecular formula is C31H48N8O6 with CAS No. 910463-68-2.
Strictly contraindicated in patients with personal or family history of medullary thyroid carcinoma. Store powder at -20°C protected from light; maintain cold chain logistics during transport to ensure stability.